ArticleFrontiers in oncology2025

The clinicopathological characteristics, oncologic outcomes and costs of "HER2-low" early breast cancer compared to HER2-zero and HER2-positive: a single-centre retrospective analysis.

Patrícia Rafaela Rodrigues et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.